Nuvo Pharmaceuticals (NRI) Sets New 12-Month Low at $1.10
Nuvo Pharmaceuticals Inc (TSE:NRI) shares hit a new 52-week low during trading on Tuesday . The company traded as low as C$1.10 and last traded at C$1.10, with a volume of 31693 shares trading hands. The stock had previously closed at C$1.20.
Separately, Bloom Burton reaffirmed a “buy” rating on shares of Nuvo Pharmaceuticals in a research report on Monday, April 1st.
The stock has a market cap of $12.50 million and a P/E ratio of -1.74. The company has a current ratio of 2.08, a quick ratio of 1.53 and a debt-to-equity ratio of 629.34.
About Nuvo Pharmaceuticals (TSE:NRI)
Nuvo Pharmaceuticals Inc, a commercial healthcare company, produces and sells pharmaceutical products in the United States, Canada, and Europe. It offers Pennsaid, a topical pain product that is used to treat the signs and symptoms of osteoarthritis of the knee; Pennsaid 2%, a follow-on product to Pennsaid for the treatment of the pain of osteoarthritis of the knee; Heated Lidocaine/Tetracaine (HLT) Patch, a topical patch that provides local analgesia prior to painful needle procedures, such as dialysis, blood draws, and pediatric needles; and Resultz, an over-the-counter product intended to kill head lice and remove their eggs from hair.
See Also: Beige Book
Receive News & Ratings for Nuvo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.